Compare Abeona Therapeutics Inc (ABEO) vs Nutanix Inc (NTNX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nutanix Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Nutanix Inc trades at $53.57 (market cap $14.53B). The key difference: Nutanix Inc is far larger — about 38.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | NTNX | |
|---|---|---|
Market Cap | $373.32M | $14.53B |
Sector | Health | Technology |
52-Week High | $7.23 | $81.12 |
52-Week Low | $4.17 | $34.41 |
Enterprise Value | $228.22M | $14.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Nutanix (NTNX) trades at $52.42, up 2.22% with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with Q3 2026 earnings beating expectations, 87% gross margins, and projected revenue growth to $2.7B in 2026. Recent NVIDIA certification for Unified Storage and expanding enterprise partnerships highlight strategic positioning in hybrid cloud infrastructure.
Outlook remains positive with 62.5% analyst buy ratings and $56.55 consensus target, though elevated P/E ratio of 55.17 and RSI near overbought levels suggest near-term consolidation risk. Key catalysts include AI infrastructure adoption and VMware migration opportunities, while execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
